|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||104495||Standard format: Plasmid sent in bacteria as agar stab||1||$75|
|AAV Retrograde||104495-AAVrg||Virus (100 µL at titer ≥ 7×10¹² vg/mL)|
This material is available to academics and nonprofits only.
Backbone manufacturerScott Sternson
- Backbone size w/o insert (bp) 5027
- Total vector size (bp) 6380
Vector typeMammalian Expression, AAV, Cre/Lox
Growth in Bacteria
Growth Strain(s)NEB Stable
Copy numberLow Copy
Alt nameGCaMP3-A52V K78H T302L R303P A317L D380Y T381R S383T R392G
Alt nameGCaMP3 variant 1473
Alt nameJanelia GCaMP7
SpeciesR. norvegicus (rat), G. gallus (chicken); A. victoria (jellyfish)
Insert Size (bp)1353
- Promoter CAG
/ Fusion Protein
- T7 epitope, Xpress tag, 6xHis
- Cloning method Restriction Enzyme
- 5′ cloning site BsmBI (destroyed during cloning)
- 3′ cloning site BsmBI (destroyed during cloning)
- 5′ sequencing primer GGTTCGGCTTCTGGCGTGTGACC (Common Sequencing Primers)
Terms and Licenses
Article Citing this Plasmid
Information for AAV Retrograde (Catalog # 104495-AAVrg) ( Back to top )
Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE (#104495). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE plasmid DNA.CAG-driven, Cre-dependent GCaMP7s calcium sensor. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
- Volume 100 µL
- Titer ≥ 7×10¹² vg/mL
- Pricing $350 USD for preparation of 100 µL virus + $30 USD for plasmid.
- Storage Store at -80℃. Thaw just before use and keep on ice.
- Shipment Viral particles are shipped frozen on dry ice. Plasmid DNA (≥ 200ng) will also be included in the shipment.
Viral Production & Use
Requestor is responsible for compliance with their institution's biosafety regulations. Lentivirus is generally considered BSL-2. AAV is generally considered BSL-1, but may require BSL-2 handling depending on the insert. Biosafety Guide
Terms and Licenses
Viral Quality Control
- Addgene ensures high quality viral vectors by optimizing and standardizing production protocols and performing rigorous quality control (QC) (see a list of our QC assays). The specific QC assays performed varies for each viral lot. To learn which specific QC assays were performed on your lot, please contact us.
- Titer: the exact titer of your sample will be reported on the tube. The titer you see listed on this page is the guaranteed minimum titer. See how titers are measured.
Visit our viral production page for more information.
Addgene CommentsRetrograde functionality is dependent on high viral titers. Addgene recommends not diluting your AAV preps prior to use.
Using FLEX vectors in vivo: LoxP sites in FLEX plasmids are known to recombine during DNA amplification and viral vector production, which may result in a minority of Cre-activated (i.e., "flipped") viral vectors. Addgene has measured this occurs in 0.01-0.03% of viral vectors in our typical production protocol. This can lead to a small number of cells exhibiting Cre-independent transgene expression in vivo. To address this, we recommend titrating to find the optimal AAV dosage required for Cre-dependent transgene expression and function in vivo. This may include reducing the viral vector dosage in order to reduce the likelihood of Cre-independent expression.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE was a gift from Douglas Kim & GENIE Project (Addgene plasmid # 104495 ; http://n2t.net/addgene:104495 ; RRID:Addgene_104495)
For viral preps, please replace (Addgene plasmid # 104495) in the above sentence with: (Addgene viral prep # 104495-AAVrg)
For your References section:High-performance GFP-based calcium indicators for imaging activity in neuronal populations and microcompartments. Dana H, Sun Y, Mohar B, Hulse B, Hasseman JP, Tsegaye G, Tsang A, Wong A, Patel R, Macklin JJ, Chen Y, Konnerth A, Jayaraman V, Looger LL, Schreiter ER, Svoboda K, Kim DS.. bioRxiv 434589 10.1101/434589